Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06536868 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Jul 31, 2026 to Dec 31, 2026v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a single arm, open, multicenter phase II study. The main purpose of this study was to evaluate preliminary efficacy and safety of Tislelizumab combined with thoracic radiotherapy as first line therapy for Extensive stage small cell lung cancer.
Trial Details
NCT Number NCT06536868
Lead Sponsor Second Hospital of Shanxi Medical University
Conditions
(from sponsor)		 Extensive-stage Small-cell Lung Cancer
Related terms Small Cell Lung Carcinoma
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov